New Jersey ranks second-lowest in smoking rate, third in lung cancer surgery, new report finds
NEW JERSEY — New Jersey has the second-lowest smoking rate in the nation and ranks third for lung cancer patients receiving surgery as their first course of treatment, according to a new report released Tuesday by the American Lung Association.
The organization’s ninth annual “State of Lung Cancer” report, released Nov. 17, also found that New Jersey’s five-year lung cancer survival rate is above the national average, although screening and early detection remain areas of concern.
According to the report, New Jersey’s smoking rate is 7.1%, compared with the national rate of 10.4%, placing the state second among 48 states measured.
New Jersey also ranks third among 40 states for surgical treatment, with 26.7% of lung cancer patients undergoing surgery as their first course of treatment, compared with 21.4% nationally.
The state’s five-year lung cancer survival rate is 33.6%, exceeding the national average of 31%. New Jersey ranks 10th among 43 states measured for survival, representing an 18% improvement over the past five years.
Lung cancer remains the leading cause of cancer deaths in New Jersey and across the United States. Nationally, more than 229,000 people are expected to be diagnosed with the disease in 2026, according to the American Lung Association.
“Overall, our report reveals positive news—more people in the U.S. are living longer after a lung cancer diagnosis than ever before, and more people are getting screened for the disease. While these findings give us hope, more must be done to end the burden of this devastating disease on families throughout New Jersey,” said Michael Seilback, assistant vice president of nationwide advocacy and state public policy for the American Lung Association. “We need to increase screening rates among those at high risk to catch the disease early when it’s more likely to be curable and improve access to clinical trials and the best lung cancer care.”
The report found that New Jersey’s rate of new lung cancer cases is 48.3 per 100,000 residents, below the national rate of 52.1 per 100,000. The state ranks 15th among 51 jurisdictions measured, with its rate improving 7% over the past five years.
Despite those improvements, New Jersey ranks 30th among 47 states for early diagnosis, with 29.1% of lung cancer cases detected at an early stage, compared with 29.3% nationally. The state’s early diagnosis rate has improved 14% over the past five years.
Lung cancer screening also remains below the national average. The report found that 23.5% of eligible high-risk New Jersey residents received screening, compared with 24.4% nationally, placing the state 28th among 50 states measured.
Annual low-dose CT scans for people at high risk can reduce lung cancer deaths by up to 20%, according to the American Lung Association.
The report also found that 20.4% of lung cancer patients in New Jersey received no treatment, compared with 20.9% nationally. The state ranks 25th among 47 states measured, with the percentage of patients receiving no treatment increasing 10% over the past five years.
New Jersey ranked eighth among 51 jurisdictions for radon, with a reported rate of 9.8%. Radon is a colorless, odorless gas that can accumulate inside homes and buildings and is the second-leading cause of lung cancer, according to the association.
The report also examined insurance coverage for comprehensive biomarker testing, which can help identify personalized lung cancer treatments, including targeted therapies and immunotherapy.
New Jersey requires insurance coverage for comprehensive biomarker testing, while 24 states and Washington, D.C., do not require any coverage, according to the report.
The American Lung Association is also urging Congress to pass the bipartisan Clinical Trial Modernization Act, which the organization says would help reduce barriers to participation in clinical trials and improve access to lung cancer research and treatment.
The association said continued efforts are needed to increase screening among high-risk individuals, improve access to treatment and expand participation in clinical trials.
The full 2026 “State of Lung Cancer” report is available at Lung.org/solc.





